Microfluidic cell culture and its application in high-throughput drug screening: Cardiotoxicity assay for hERG channels

Journal of Biomolecular Screening

Volumn 16, Issue 1, 2011, Pages 101-111

  Su, Xiaojing ^a   Young, Edmond W K ^a   Underkofler, Heather A S ^b   Kamp, Timothy J ^b   January, Craig T ^b   Beebe, David J ^a  

^a University of Wisconsin Health   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

cell culture; drug screening; fluoxetine; hERG; high throughput; live cell Western; microfluidics

Indexed keywords

ACETYLSALICYLIC ACID; ALKENE; ARSENIC TRIOXIDE; DIMETICONE; FLUOXETINE; IVERMECTIN; PARACETAMOL; POLYSTYRENE; POTASSIUM CHANNEL HERG;

ARTICLE; CARDIOTOXICITY; CELL CULTURE; CELL GROWTH; CELL LYSATE; CELL MEMBRANE; CELL MIGRATION; CELL PROLIFERATION; CELL STRUCTURE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG SCREENING; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; MICROFLUIDICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

CELL CULTURE TECHNIQUES; DRUG EVALUATION, PRECLINICAL; ETHER-A-GO-GO POTASSIUM CHANNELS; HEK293 CELLS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; ION TRANSPORT; LONG QT SYNDROME; MICROFLUIDICS; POLYMERS; POTASSIUM CHANNEL BLOCKERS;

EID: 78951473463     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057110386218     Document Type: Article

References (44)

1. Kongsamut S., Kang J., Chen X., Roehr J., Rampe D.: A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs. Eur J Pharmacol 2002 ; 450: 37-41.
2. Netzer R., Ebneth A., Bischoff U., Pongs O.: Screening lead compounds for QT interval prolongation. Drug Discov Today 2001 ; 6: 78-84.
3. Hancox J., McPate M., Harchi AE, Zhang Y.: The hERG potassium channel and hERG screening for drug-induced torsades de pointes. Pharmacol Ther 2008 ; 119: 118-132.
4. Ficker E., Kuryshev Y., Dennis A., Obejero-Paz C., Lu W., Hawryluk P.,, et al. Mechanisms of arsenic-induced prolongation of cardiac repolarization. Mol Pharmacol 2004 ; 66: 33-44.
5. Traebert M., Dumotier B., Meister L., Hoffmann P., Dominguez-Estevez M., Suter W.: Inhibition of hERG K+ currents by antimalarial drugs in stably transfected HEK293 cells. Eur J Pharmacol 2004 ; 484: 41-48.
6. Kim K., Kim E.: The phenothiazine drugs inhibit hERG potassium channels. Drug Chem Toxicol 2005 ; 28: 303-313.
7. Zhou Z., Vorperian V., Gong Q., Zhang S., January C.: Block of HERG potassium channels by the antihistamine astemizole and its metabolites desmethylastemizole and norastemizole. J Cardiovasc Electrophysiol 1999 ; 10: 836-843.
8. Snyders D., Chaudhary A.: High affinity open channel block by dofetilide of HERG expressed in a human cell line. Mol Pharmacol 1996 ; 49: 949-955.
9. Yang T., Snyders D., Roden D.: Drug block of I-kappa r: Model systems and relevance to human arrhythmias. J Cardiovasc Pharmacol 2001 ; 38: 737-744.
10. Sanguinetti M., Tristani-Firouzi M.: hERG potassium channels and cardiac arrhythmia. Nature 2006 ; 440: 463-469.
11. Cheng C., Alderman D., Kwash J., Dessaint J., Patel R., Lescoe M.,, et al. A high-throughput HERG potassium channel function assay: an old assay with a new look. Drug Dev Ind Pharm 2002 ; 28: 177-191.
12. Dubin A., Nasser N., Rohrbacher J., Hermans A., Marrannes R., Grantham C.,, et al. Identifying modulators of hERG channel activity using the PatchXpress planar patch clamp. J Biomol Screen 2005 ; 10: 168-181.
13. Finlayson K., Witchel H., McCulloch J., Sharkey J.: Acquired QT interval prolongation and HERG: implications for drug discovery and development. Eur J Pharmacol 2004 ; 500: 129-142.
14. Delisle BP, Underkofler HAS, Moungey BM, Slind JK, Kilby JA, Best JM,, et al. Small GTPase determinants for the Golgi processing and plasmalemmal expression of human ether-a-go-go related (hERG) K+ channels. J Biol Chem 2009 ; 284: 2844-2853.
15. Wible BA, Hawryluk P., Ficker E., Kuryshev YA, Kirsch G., Brown AM: HERG-Lite: a novel comprehensive high-throughput screen for drug-induced hERG risk. J Pharmacol Toxicol Methods 2005 ; 52: 136-145.
16. Adams CP, Brantner VV: Spending on new drug development. Health Econ 2010 ; 19: 130-141.
17. DiMasi JA, Feldman L., Seckler A., Wilson A.: Trends in risks associated with new drug development: success rates for investigational drugs. Clin Pharmacol Ther 2010 ; 87: 272-277.
18. DiMasi J., Hansen R., Grabowski H.: The price of innovation: new estimates of drug development costs. J Health Econ 2003 ; 22: 151-185.
19. Orloff J., Douglas F., Pinheiro J., Levinson S., Branson M., Chaturvedi P.,, et al. A guide to drug discovery-opinion: the future of drug development: advancing clinical trial design. Nat Rev Drug Discov 2009 ; 8: 949-957.
20. Domenech M., Yu H., Warrick J., Badders N., Meyvantsson I., Alexander C.,, et al. Cellular observations enabled by microculture: paracrine signaling and population demographics. Integr Biol 2009 ; 1: 267-274.
21. Gao D., Liu J., Wei H., Li H., Guo G., Lin J.: A microfluidic approach for anticancer drug analysis based on hydrogel encapsulated tumor cells. Analytica Chimica Acta 2010 ; 665: 7-14.
22. van der Meer AD, Vermeul K., Poot AA, Feijen J., Vermes I.: A microfluidic wound-healing assay for quantifying endothelial cell migration. Am J Physiol 2010 ; 298: H719 - H725.
23. Paguirigan A., Puccinelli J., Su X., Beebe DJ: Expanding the available assays: adapting and validating in-cell Westerns in microfluidic devices for high throughput cell based assays. Assay Drug Dev Technol 2010 ; 8: 591-601.
24. Paguirigan A., Beebe DJ: From the cellular perspective: exploring differences in the cellular baseline in macroscale and microfluidic cultures. Integr Biol 2009 ; 1: 182-195.
25. Puccinelli J., Su X., Beebe DJ: Automated high-throughput microchannel assays for cell biology: operational optimization and characterization. J Assoc Lab Automation 2010 ; 15: 25-32.
26. Shao J., Wu L., Wu J., Zheng Y., Zhao H., Jin Q.,, et al. Integrated microfluidic chip for endothelial cells culture and analysis exposed to a pulsatile and oscillatory shear stress. Lab Chip 2009 ; 9: 3118-3125.
27. Song J., Cavnar S., Walker A., Luker K., Gupta M., Tung Y.,, et al. Microfluidic endothelium for studying the intravascular adhesion of metastatic breast cancer cells. PLoS ONE 2009 ; 4: e5756.
28. Young EWK, Wheeler AR, Simmons CA: Matrix-dependent adhesion of vascular and valvular endothelial cells in microfluidic channels. Lab Chip 2007 ; 7: 1759-1766.
29. Young EWK, Watson MWL, Srigunapalan S., Wheeler AR, Simmons CA: Technique for real-time measurements of endothelial permeability in a microfluidic membrane chip using laser-induced fluorescence detection. Anal Chem 2010 ; 82: 808-816.
30. Young EWK, Beebe DJ: Fundamentals of microfluidic cell culture in controlled microenvironments. Chem Soc Rev 2010 ; 39: 1036-1048.
31. Berthier E., Beebe DJ: Flow rate analysis of a surface tension driven passive micropump. Lab Chip 2007 ; 7: 1475-1478.
32. Walker G., Beebe DJ: A passive pumping method for microfluidic devices. Lab Chip 2002 ; 2: 131-134.
33. Duffy D., McDonald J., Schueller O., Whitesides G.: Rapid prototyping of microfluidic systems in poly(dimethylsiloxane). Anal Chem 1998 ; 70: 4974-4984.
34. Zhou Z., Gong Q., Epstein M., January C.: HERG channel dysfunction in human long QT syndrome: intracellular transport and functional defects. J Biol Chem 1998 ; 273: 21061-21066.
35. Zhou Z., Gong Q., Ye B., Fan Z., Makielski J., Robertson G.,, et al. Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature. Biophys J 1998 ; 74: 230-241.
36. Paguirigan A., Beebe DJ: Microfluidics meet cell biology: bridging the gap by validation and application of microscale techniques for cell biological assays. Bioessays 2008 ; 30: 811-821.
37. Rajamani S., Eckhardt L., Valdivia C., Klemens C., Gillman B., Anderson C.,, et al. Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine. Br J Pharmacol 2006 ; 149: 481-489.
38. Gomez-Sjoberg R., Leyrat A., Pirone D., Chen C., Quake S.: Versatile, fully automated, microfluidic cell culture system. Anal Chem 2007 ; 79: 8557-8563.
39. Meyvantsson I., Warrick J., Hayes S., Skoien A., Beebe DJ: Automated cell culture in high density tubeless microfluidic device arrays. Lab Chip 2008 ; 8: 717-724.
40. Terstappen G.: Nonradioactive rubidium ion efflux assay and its applications in drug discovery and development. Assay Drug Dev Technol 2004 ; 2: 553-559.
41. Finlayson K., Turnbull L., January C., Sharkey J., Kelly J.: [H-3]dofetilide binding to HERG transfected membranes: a potential high throughput preclinical screen. Eur J Pharmacol 2001 ; 430: 147-148.
42. Regehr KJ, Domenech M., Koepsel JT, Carver KC, Ellison-Zelski SJ, Murphy WL,, et al. Biological implications of polydimethylsiloxane-based microfluidic cell culture. Lab Chip 2009 ; 9: 2132-2139.
43. Toepke M., Beebe DJ: PDMS absorption of small molecules and consequences in microfluidic applications. Lab Chip 2006 ; 6: 1484-1486.
44. Schaddelee M., Groenendaal D., DeJongh J., Cleypool C., IJzerman A., De Boer A.,, et al. Population pharmacokinetic modeling of blood-brain barrier transport of synthetic adenosine A(1) receptor agonists. J Pharmacol Exp Ther 2004 ; 311: 1138-1146.